Immune checkpoint inhibitors have greatly altered the treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC). Initially confined to treatment of advanced disease, the anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) are now approved in earlier treatment settings. Keytruda is now poised to become the standard of care in the first-line setting in combination with the antibody-drug conjugate Padcev (Seagen / Astellas) in cisplatin-ineligible patients. In the high-risk BCG-unresponsive population, Adstiladrin (Ferring Pharmaceuticals) is the first gene therapy available to treat bladder cancer in the United States. The approval of Bavencio (Merck KGaA / Pfizer) as maintenance therapy for first-line locally advanced or metastatic urothelial carcinoma highlights the expanded use of immune checkpoint inhibitors in all lines of therapy across the geographies covered. The initial entry of antibody-drug conjugates Padcev and Trodelvy (Gilead) has diversified the treatment paradigm for previously treated advanced or metastatic disease. Several new therapies and combinations, anticipated to be approved by 2032, will only intensify the competition in this market.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.